Effects of statin therapy on serum trace element status in dyslipidemic patients: Results of a randomized placebo-controlled cross-over trial

Clinical Laboratory

Volumn 58, Issue 9-10, 2012, Pages 1005-1015

  Farrokhi, Farid ^a   Moohebati, Mohsen ^b   Aghdaei, Hamid Reza Assadzadeh ^c   Ghaffarzadegan, Kamran ^a   Norouzi, Farzaneh ^b   Sahebkar, Amirhossein ^b,d   Tavallaie, Shima ^b,d   Azarpazhooh, Mahmoud Reza ^b   Ghayour Mobarhan, Majid ^b,d   Ferns, Gordon A ^e  

^a RAZAVI HOSPITAL   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e KEELE UNIVERSITY   (United Kingdom)

Author keywords

Ceruloplasmin; Clinical trial; Copper; Dyslipidemia; Selenium; Statin; Superoxide dismutase; Zinc

Indexed keywords

CERULOPLASMIN; COPPER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; SELENIUM; SIMVASTATIN; SUPEROXIDE DISMUTASE; TRACE ELEMENT; ZINC;

ADULT; ARTICLE; ATHEROSCLEROSIS; BLOOD LEVEL; BLOOD PRESSURE; BODY MASS; BODY WEIGHT; CERULOPLASMIN BLOOD LEVEL; CONTROLLED STUDY; COPPER BLOOD LEVEL; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DYSLIPIDEMIA; ENZYME ACTIVITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; ZINC BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; CERULOPLASMIN; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; SIMVASTATIN; SUPEROXIDE DISMUTASE; TRACE ELEMENTS; YOUNG ADULT;

EID: 84868552883     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: 10.7754/Clin.Lab.2011.111120     Document Type: Article

References (51)

1. Wenger NK, Lewis SJ. Use of statin therapy to reduce cardiovascular risk in older patients. Curr Gerontol Geriatr Res 2010:915296.
2. Moohebati M, Bidmeshgi S, Azarpazhooh MR, et al. Simvastatin treatment reduces heat shock protein 60, 65, and 70 antibody titers in dyslipidemic patients: A randomized, double-blind, placebo-controlled, cross-over trial. Clin Biochem 2011;44:192-7.
3. Resch U, Tatzber F, Budinsky A, Sinzinger H. Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy. Br J Clin Pharmacol 2006;61:262-74. (Pubitemid 43382625)
4. Shovman O, Levy Y, Gilburd B, Shoenfeld Y. Antiinflammatory and immunomodulatory properties of statins. Immunol Res 2002;25:271-85. (Pubitemid 34454717)
5. Parizadeh SM, Azarpazhooh MR, Moohebati M, et al. Simvastatin therapy reduces prooxidant-antioxidant balance: results of a placebo-controlled cross-over trial. Lipids 2011;46:333-40.
6. Houston MC. The role of cellular micronutrient analysis, nutraceuticals, vitamins, antioxidants and minerals in the prevention and treatment of hypertension and cardiovascular disease. Ther Adv Cardiovasc Dis 2010;4:165-83.
7. Tan C, Chen H, Xia C. The prediction of cardiovascular disease based on trace element contents in hair and a classifier of boosting decision stumps. Biol Trace Elem Res 2009;129:9-19.
8. Leopold JA, Loscalzo J. Oxidative risk for atherothrombotic cardiovascular disease. Free Radical Biology and Medicine 2009;47:1673-706.
9. Walsh CT, Sandstead HH, Prasad AS, Newberne PM, Fraker PJ. Zinc: health effects and research priorities for the 1990s. Environ Health Perspect 1994;102:5-46. (Pubitemid 24217794)
10. Prasad AS. Zinc: mechanisms of host defense. J Nutr 2006;137:1345-9. (Pubitemid 46701933)
11. Reunanen A, Knekt P, Marniemi J, Mäki J, Maatela J, Aromaa A. Serum calcium, magnesium, copper and zinc and risk of cardiovascular death. Eur J Clin Nutr 1996;50:431-7. (Pubitemid 26246073)
12. Soinio M, Marniemi J, Laakso M, Pyörälä K, Lehto S, Rönnemaa T. Serum zinc level and coronary heart disease events in patients with type 2 diabetes. Diabetes Care 2007;30:523-8. (Pubitemid 46354328)
13. Mocchegiani E, Malavolta M, Marcellini F, et al. Zinc, oxidative stress, genetic background and immunosenescence: implications for healthy aging. Immun Ageing 2006;3:6.
14. Hooper PL, Visconti L, Garry PJ, Johnson GE. Zinc lowers high-density lipoprotein-cholesterol levels. J Am Med Assoc 1980;244:1960-1. (Pubitemid 10014997)
15. Mezzetti A, Pierdomenico SD, Costantini F, et al. Copper/zinc ratio and systemic oxidant load: effect of aging and aging-related degenerative diseases. Free Radic Biol Med 1998;25:676-81. (Pubitemid 28464933)
16. Shukla N, Maher J, Masters J, Angelini GD, Jeremy JY. Does oxidative stress change ceruloplasmin from a protective to a vasculopathic factor? Atherosclerosis 2006;187:238-50. (Pubitemid 43963031)
17. Wattanapitayakul SK, Bauer JA. Oxidative pathways in cardiovascular disease: roles, mechanisms, and therapeutic implications. Pharmacol Ther 2001;89:187-206. (Pubitemid 32333040)
18. Yilmaz M, Baykal Y, Kilic M, et al. Effects of statins on oxidative stress. Biol Trace Elem Res 2004;98:119-27. (Pubitemid 38608547)
19. Rayman MP. The importance of selenium to human health. Lancet 2000;356:233-41. (Pubitemid 30446984)
20. Flores-Mateo G, Navas-Acien A, Pastor-Barriuso R, Guallar E. Selenium and coronary heart disease: a meta-analysis. Am J Clin Nutr 2006;84:762-73. (Pubitemid 44715658)
21. Neve J. Selenium as a risk factor for cardiovascular diseases. J Cardiovasc Risk 1996;3:42-7. (Pubitemid 26184617)
22. Huang K, Liu H, Chen Z, Xu H. Role of selenium in cytoprotection against cholesterol oxide-induced vascular damage in rats. Atherosclerosis 2002;162:137-44. (Pubitemid 34327351)
23. de Lorgeril M, Salen P. Selenium and antioxidant defenses as major mediators in the development of chronic heart failure. Heart Fail Rev 2006;11:13-7. (Pubitemid 43986204)
24. Luoma PV, Sotaniemi EA, Korpela H, Kumpulainen J. Serum selenium, glutathione peroxidase activity and high-density lipoprotein cholesterol - effect of selenium supplementation. Res Commun Chem Pathol Pharmacol 1984;46:469-72. (Pubitemid 15181834)
25. Salonen JT, Salonen R, Seppanen K, et al. Relationship of serum selenium and antioxidants to plasma lipoproteins, platelet aggregability and prevalent ischaemic heart disease in Eastern Finnish men. Atherosclerosis 1988;70:155-60. (Pubitemid 18091712)
26. Ferns GAA, Lamb DJ, Taylor A. The possible role of copper ions in atherogenesis: the Blue Janus. Atherosclerosis 1997;133:139-52. (Pubitemid 27373491)
27. Klevay LM. Dietary copper and risk of coronary heart disease. Am J Clin Nutr 2000;71:1213-4. (Pubitemid 30230573)
28. Hajipour B, Somi MH, Dibazar F, Asl NA, Vatankhah AM. Anti-oxidative effect of simvastatin in liver and lung tissue after hepatic ischemia/reperfusion in rat. Journal of Medical Sciences 2010;10:66-70.
29. Ghayour-Mobarhan M, Lamb DJ, Taylor A, et al. Effect of statin therapy on serum trace element status in dyslipidaemic subjects. J Trace Elem Med Biol 2005;19(1):61-7. (Pubitemid 41253919)
30. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
31. Taylor A. Measurement of zinc in clinical samples. Ann Clin Biochem 1997;34:142-50. (Pubitemid 27121034)
32. Campillo N, Vinas P, Lopez-Garcia I, Hernandez-Cordoba M. Selenium determination in biological fluids using Zeeman background correction electrothermal atomic absorption spectrometry. Anal Biochem 2000;280:195-200. (Pubitemid 30308072)
33. Sunderman FW, Jr., Nomoto S. Measurement of human serum ceruloplasmin by its p-phenylenediamine oxidase activity. Clin Chem 1970;16:903-10.
34. Taccone-Gallucci M, Noce A, Bertucci P, et al. Chronic treatment with statins increases the availability of selenium in the antioxidant defence systems of hemodialysis patients. J Trace Elem Med Biol 2010;24:27-30.
35. Paik H, Joung H, Lee J, Lee H, King J, Keen C. Serum extracellular superoxide dismutase activity as an indicator of zinc status in humans. Biol Trace Elem Res 1999;69:45-57. (Pubitemid 29270223)
36. Reunanen A, Knekt P, Marniemi J, Mäki J, Maatela J, Aromaa A. Serum calcium, magnesium, copper and zinc and risk of cardiovascular death. Eur J Clin Nutr 1996;50:431-7. (Pubitemid 26246073)
37. Shokrzadeh M, Ghaemian A, Salehifar E, Aliakbari S, Saravi SS, Ebrahimi P. Serum zinc and copper levels in ischemic cardiomyopathy. Biol Trace Elem Res 2009;127:116-23.
38. Leonhardt W, Kurktschiev T, Meissner D, et al. Effects of fluvastatin therapy on lipids, antioxidants, oxidation of low density lipoproteins and trace metals. Eur J Clin Pharmacol 1997;53:65-9. (Pubitemid 27430032)
39. Fowler DM, Cooper SJ, Stephany JJ, Hendon N, Nelson S, Fields S. Suppression of statin effectiveness by copper and zinc in yeast and human cells. Mol Biosyst 2011;7:533-44.
40. Arnaud J, Akbaraly TN, Hininger-Favier I, Berr C, Roussel AM. Fibrates but not statins increase plasma selenium in dyslipidemic aged patients - the EVA study. J Trace Elem Med Biol 2009;23:21-8.
41. Buyukhatipoglu H, Sezen Y, Yildiz A, et al. Effects of statin use on total oxidant and antoxidant capacity and ceruloplasmin activity. Clin Invest Med 2010;33:E313-20.
42. Kosenko EA, Suslikov AV, Venediktova NI, Kaminskil IG. Antioxidant enzymes in erythrocytes from hypertension patients receiving lisinopril monotherapy or combined lisinopril plus simvastatin therapy. Biomeditsinskaia khimiia 2011;57:335-42.
43. Kowalski J, Pawlicki L, Grycewicz J, et al. Estimation of anti-oxidative effect of atorvastatin and fluvastatin used in primary prevention of coronary heart disease - effect on antioxidative enzymatic activity. Wiadomości lekarskie (Warsaw, Poland: 1960) 2005;58:275-9.
44. Kowalski J, Olejniczak J, Błaszczyk J, et al. Effect of fluvastatin and fenofibrate on the antioxidative barrier enzyme activity in patients with dyslipidemia. Polski Merkuriusz Lekarski 2003;14:285-8. (Pubitemid 36542028)
45. Ungureanu D, Filip C, Artenie A, Artenie R. Evaluation of simvastatin antioxidant effects. Revista medico-chirurgicala a Societaţii de Medici şi̧ Naturalişţi din Iaşi̧ 2003;107:66-71.
46. Sparks DL, Sabbagh MN, Connor DJ, et al. Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate AD. Curr Alzheimer Res 2005;2:343-53. (Pubitemid 40980193)
47. Carrepeiro MM, Rogero MM, Bertolami MC, Botelho PB, Castro N, Castro IA. Effect of n-3 fatty acids and statins on oxidative stress in statin-treated hypercholesterolemic and normocholesterolemic women. Atherosclerosis 2011;217:171-8.
48. Zhiyou C, Yong Y, Yonglong W. Atorvastatin attenuates oxidetive stress in Alzheimer's disease. J Med Coll PLA 2008;23:31-7.
49. Sola S, Mir MQS, Lerakis S, Tandon N, Khan BV. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol. 2006;47:332-7. (Pubitemid 43063250)
50. Save V, Patil N, Moulik N, Rajadhyaksha G. Effect of atorvastatin on type 2 diabetic dyslipidemia. J Cardiovasc Pharmacol Ther 2006;11:262-70. (Pubitemid 44936240)
51. Taccone-Gallucci M, Noce A, Bertucci P, et al. Chronic treatment with statins increases the availability of selenium in the antioxidant defense systems of hemodialysis patients. J Trace Elem Med Biol 2010;24:27-30.